Cryo and epigenetic reprogramming offer dual paths to extend healthy lifespan
Reversible cryopreservation could pause terminal illness until cures exist, while epigenetic reprogramming resets aged cells to youthful function; both approaches are approaching human-rele…
Rat kidney cryopreservation success paves way for human organ banking
Vitrification with nanoparticle rewarming achieved reversible rat kidney preservation; scaling to pig organs could eliminate transplant logistics bottlenecks and create a viable organ banki…
AI cuts drug discovery time in half for longevity startups
Foundation models combining protein/DNA sequences with LLM embeddings predict transcription factor effects, explaining 50% of experimental variation in silico and enabling 2x faster discove…
Virtual cell models require orders of magnitude more human trial data to predict toxicity
Current human drug trial data (~2,000 new drugs/year) is insufficient to train predictive toxicity models; decades needed unless data collection radically accelerates.
GLP-1 drugs join statins as proven longevity therapeutics
Health economics data shows GLP-1 agonists add 1-3 years of healthy life, comparable to statins, establishing a widely used longevity medicine class that could stack for further gains.
AI-driven deep phenotyping may shrink clinical trials and revive pharma productivity
High-content measurements and AI prediction could reduce patient numbers needed per trial, increasing throughput and potentially bending the cost curve of drug development (reversing Eroom'…